InMed Pharmaceuticals Inc. (INM) — Institutional Holders, Q2 2026
20 institutional investment managers reported a INM position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $4.0M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
INM in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- ADAR1 Capital ManagementNew · +800,000 sh+$1.2M
- Vivo CapitalNew · +798,377 sh+$1.2M
- Squadron Capital ManagementNew · +325,000 sh+$503.8K
- Ikarian CapitalNew · +245,025 sh+$379.8K
- SUVRETTA CAPITAL MANAGEMENTNew · +100,000 sh+$155.0K
Biggest sellers
- SABBY MANAGEMENTTrimmed · -175,290 sh-$271.7K
- CITADEL ADVISORSTrimmed · -20,889 sh-$32.4K
- Virtu FinancialSold out · -19,980 sh-$31.0K
- UBS Group AGSold out · -8,068 sh-$12.5K
- TWO SIGMA SECURITIESTrimmed · -7,773 sh-$12.0K
INM 13F holders ranked 1–20 of 20
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | ADAR1 Capital Management#1 · 800,000 sh | 800,000 | $1.2M | 0.06% | New |
| 2 | Vivo Capital#2 · 798,377 sh | 798,377 | $1.2M | 0.11% | New |
| 3 | Squadron Capital Management#3 · 325,000 sh | 325,000 | $503.8K | 0.16% | New |
| 4 | Ikarian Capital#4 · 245,025 sh | 245,025 | $379.8K | 0.04% | New |
| 5 | SUVRETTA CAPITAL MANAGEMENT#5 · 100,000 sh | 100,000 | $155.0K | <0.01% | New |
| 6 | BOOTHBAY FUND MANAGEMENT#6 · 74,244 sh | 74,244 | $115.1K | <0.01% | New |
| 7 | SABBY MANAGEMENT#7 · 44,970 sh | 44,970 | $69.7K | 0.06% | -79.6% |
| 8 | JANE STREET GROUP#8 · 43,078 sh | 43,078 | $66.8K | 0.00% | New |
| 9 | VR Adviser#9 · 32,685 sh | 32,685 | $50.7K | <0.01% | New |
| 10 | CITADEL ADVISORS#10 · 26,084 sh | 26,084 | $40.4K | 0.00% | -44.5% |
| 11 | SEVEN GRAND MANAGERS#11 · 25,000 sh | 25,000 | $38.8K | <0.01% | New |
| 12 | Scientech Research#12 · 15,461 sh | 15,461 | $24.0K | 0.02% | New |
| 13 | Crestwood Advisors Group#13 · 14,900 sh | 14,900 | $23.1K | <0.01% | New |
| 14 | TWO SIGMA SECURITIES#14 · 10,945 sh | 10,945 | $17.0K | <0.01% | -41.5% |
| 15 | Stratos Wealth Partners, LTD.#15 · 10,760 sh | 10,760 | $16.7K | <0.01% | New |
| 16 | Private Wealth Management Group#16 · 5,000 sh | 5,000 | $7.8K | — | 0.0% |
| 17 | Banque Cantonale Vaudoise#17 · 6 sh | 6 | $1.0K | 0.00% | 0.0% |
| 18 | SBI Securities , Ltd.#18 · 300 sh | 300 | $465.00 | — | 0.0% |
| 19 | Federation des caisses Desjardins du Quebec#19 · 2 sh | 2 | $4.00 | 0.00% | 0.0% |
| 20 | Ursa Fund Management#20 · 125,800 sh | 125,800 | — | — | New |
Funds that sold out of INM in Q2 2026 (2)
Held INM at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| Virtu Financial19,980 sh | 19,980 | $13.0K |
| UBS Group AG8,068 sh | 8,068 | $5.2K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.